Biostar Stem Cell Technology Research Institute has received Japan's MHLW approval for its angel stem cell therapy for ASD.

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.

A new pill that combats antibiotic-resistant strains of gonorrhoea is closer to US approval, after the FDA accepted GSK’s gepotidacin for priority review.

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Boehringer's Hernexeos is now FDA-approved for patients with HER2-positive NSCLC, bringing it into direct competition with ADC Enhertu.

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.